Type1diabetes
Conditions
Brief summary
This is a study of the Minimed 670G 4.0 insulin pump, assessing the efficacy of the Advanced Hybrid Closed Loop (AHCL) algorithm in controlling blood glucose levels in Type 1 Diabetes.
Detailed description
Insulin delivery systems are an increasingly popular treatment option for Type I Diabetes (T1D). Delivery systems consist of an insulin pump, a glucose sensor with a transmitter attached, and a maths program (algorithm) built into the pump. The algorithm uses sensor glucose levels to decide how much insulin should be delivered by the pump. This study aims to see how well a new algorithm controls blood glucose levels in T1D. The study uses the MiniMed 670G 4.0 insulin pump and compares two different algorithms: 1. Advanced Hybrid Closed Loop (AHCL - the new algorithm) 2. Sensor augmented pump therapy with predictive low-glucose management (SAP with PLGM). Approximately 60 participants with T1D, aged 7 - 80 years, will take part in the study. Every participant will receive the following two treatment algorithms in random order, with a two-week washout between treatments: * MiniMed 670G 4.0 insulin pump in AHCL mode for 4 weeks. * MiniMed 670G 4.0 insulin pump in SAP + PLGM mode for 4 weeks. During the study insulin pump data will be uploaded and changes in health will be monitored. In addition, participants will complete 3-day food diaries and a number of questionnaires. Participants at the Dunedin site will also be asked to complete home sleep studies during the trial (optional). The results of the study will be used to further develop insulin delivery systems. It is hoped this may improve treatment for people with diabetes.
Interventions
DEVICEAHCL
Closed loop algorithm contained in the MiniMed™ 670G 4.0 pump to be used in the study; includes a modified proportional integrative derivative (PID) model, with insulin feedback, an auto correction bolus feature and additional safety features.
DEVICESAP+PLGM
Sensor Augmented Pump (SAP) Therapy Mode with Predictive Low Glucose Management (PLGM), contained in the the MiniMed™ 670G 4.0 pump to be used in the study.
Sponsors
Medtronic
Christchurch Clinical Studies Trust Ltd
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
7 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female aged 7 - 80 years inclusive. 2. Type I diabetes as per the American Diabetes Association Classification, diagnosed at least 1 year prior to Study Day 1. 3. On insulin pump therapy for at least 6 months prior to study Day 1. 4. Minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8 units. 5. Willing and able to adhere to the study protocol. 6. Access to the internet and a computer system that meets requirements for uploading the study pump.
Exclusion criteria
1. Mean HbA1c more than 10.0% (86 mmol/mol) within 6 months prior to Study Day 1 (minimum of one test). 2. Use of a medication indicative of diabetes complications (ACE inhibitors and statins are permitted). 3. Use of systemic glucocorticoids within 2 weeks prior to the Baseline visit. 4. Current use of SGLT-2 or GLP-1 medications. 5. History or current evidence of significant seizure disorder, renal impairment or cardiovascular disease (including uncontrolled hypertension), in the opinion of the Investigator. 6. History of severe visual impairment, in the opinion of the Investigator. 7. If female, is pregnant or plans to become pregnant while participating in the study. A positive urine pregnancy test at Screening is exclusionary. 8. Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Performance of the AHCL system | 4 weeks | percentage of sensor glucose values between 3.9 - 10.0 mmol/L |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety of the AHCL system | 4 weeks | percentage of sensor glucose values \<3.9 mmol/L and \> 10 mmol/L |
Countries
New Zealand
Outcome results
None listed